Search

You searched for "stone"

1206 results found

Uroscopy

1 September 2017 | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You may feel somewhat distanced from the medical practitioners of mediaeval Florence but...

RSM Paediatric Urology Meeting and Presidential Address 2023

4 March 2024 | | URO - Paediatric Urology
The academic year of the Urological Section of the Royal Society of Medicine (RSM) started with a bang in October last year with the Paediatric Urology meeting, co-organised by Shabnam Undre (Paediatric Representative for BAUS and Consultant Paediatric Urologist East...

Unlocking the potential of AI chatbots

4 March 2024 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Infection, URO - Functional / Reconstructive Urology, URO - Neurourology, URO - Paediatric Urology, URO - Technology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology
The landscape of artificial intelligence (AI) is evolving rapidly, and one of its most exciting domains is large language models (LLMs) powering AI chatbots. These models hold immense potential to transform how we interact with technology, offering personalised assistance in...

Clear cell urothelial carcinoma: a highly aggressive morphological variant in the bladder and upper urinary tract

2 November 2023 | | URO - Urologic Oncology
Clear cell urothelial carcinoma (CCUC) is a rare morphological variant of transitional cell carcinoma (TCC). It can occur anywhere along the urothelial tract and is characterised histologically by high grade carcinoma with an abundance of clear, glycogen-rich cytoplasm [1]. Alternative...

Sarcomatoid renal cell carcinoma

1 September 2017 | | URO - Urologic Oncology
Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

Focal therapies in prostate cancer

1 November 2018 | | URO - Urologic Oncology, URO - Technology
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Rishi Sunak joins Prostate Cancer Research as an ambassador

26 February 2025 | Charities, Research & Development
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...

In conversation with Ahmed Ali

12 May 2025 | URO - Core Urology
We were delighted to chat to Ahmed Ali about the journey to pursing a urological career in the UK and his decision to found the Arabic-British Urological Society. You grew up in Iraq and went to university in Baghdad; what...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

The multidisciplinary team meeting: London calling!

1 January 2015 | | URO - Technology
The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | URO - Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...